Participated · Equity · Aug 2024

Tiimo is a Copenhagen-based provider of a neurodivergent planning and learning app that helps users manage daily time, productivity and executive-function challenges. The app offers a visual timer, widget and calendar integration, AI checklists, preset routines, and community and expert-led learning. Tiimo recently launched Tiimo Learn, a learning platform with specialist educational content, expert advice and research-backed tools for neurodivergent users. Led by Helene Lassen Nørlem and Melissa Würtz Azari, the product targets users who struggle with goal-setting, time management and focus. The app has surpassed 500K free users worldwide. Tiimo raised $1.6M in the latest round to expand operations and business reach, bringing total funding to $4.8M pre-series A.

Participated · Series A · Jan 2023

LinusBio develops precision exposome biomarkers from a single strand of hair to enable diagnostics and target discovery across conditions such as autism, GI disorders, ALS, renal disease and cancer. Its lead diagnostic aid, StrandDx™ASD, can assess likelihood of autism at birth with 80–90% accuracy, has received FDA Breakthrough Designation, and is on track to be offered as a laboratory developed test (LDT) by H1 2024. The company intends to use new funding to scale production of StrandDx™ASD at a newly opened facility in North Brunswick, New Jersey, and to extend international partnerships. LinusBio will collaborate with Y.A.C. Holdings on hardware innovation, robotics and laboratory automation to increase testing volume. The company reported it is on track for revenue growth of over 300% year‑over‑year. Over the past 18 months LinusBio has raised more than $25.5M, and its post‑money valuation increased by 35% in the current round. LinusBio develops a precision exposome sequencing platform that bridges genomics, environmental exposure, and biological response by analyzing a single strand of hair. Using proprietary laser and robotics, the platform collects thousands of data points the company says are equivalent to more than 500 liquid biopsies or blood samples and maps molecular dynamics in a time-dependent manner. Its early product, StrandDx‑ASD, can assess likelihood of autism at birth with reported 80–90% accuracy and has received FDA Breakthrough Device designation and a CE Mark in the EU as a diagnostic aid. The company is already using the platform in two pharma‑sponsored trials and is partnering with multiple organizations across the healthcare and pharma ecosystem. LinusBio’s pipeline focuses initially on neurological disorders and includes programs in ALS, oncology (including pediatric cancer), gastroenterology (IBD), renal disease, and mental disorders such as psychosis and schizophrenia. The funding will be used to grow the team, scale the platform, and deliver measurable clinical outcomes across more health conditions.

Participated · Equity · Nov 2021

Valera Health operates a virtual behavioral healthcare practice that delivers comprehensive, longitudinal care through a team-based model of licensed therapists, nurse practitioners, case managers and psychiatrists augmented by proprietary digital technology and analytics. The company emphasizes evidence-based treatment plans and a quality strategy aligned to NCQA HEDIS measures to manage patients across acuity levels, from mild depression to schizophrenia. Valera partners closely with health systems and health plans, and its payer/provider partnerships collectively cover over 50 million lives. It offers culturally-intentional care to BIPOC and LGBTQ+ communities via a diverse, multilingual provider network in which more than 50% of clinicians self-identify as Black, Hispanic, or Asian. Valera says the financing will enable expansion of access to high-quality behavioral health care and deepen partnerships with leading health systems and health plans. The company closed a $44.5M growth equity round in late 2022 as part of its current financial position. Valera Health is a NYC-based mental health company delivering tech-driven virtual services. It provides comprehensive longitudinal care via a team-based model of coaches, therapists, and medication prescribers augmented by proprietary digital technology and analytics. The company treats conditions ranging from mild depression to severe schizophrenia and offers personalized, culturally intentional care for rural and urban communities, including BIPOC and LGBTQ+ patients, through a diverse, multilingual provider network. Over the past twelve months Valera has partnered with health plans and provider groups covering over 12 million lives. Valera intends to use the newly raised $15M to expand operations and business reach and will be expanding to multiple states in the coming months. The company is led by co-founder and CEO Dr. Thomas Tsang. Valera Health is a Brooklyn, N.Y.-based tele-behavioral health service that delivers longitudinal, team-based clinical care using coaches, therapists and medication prescribers augmented by proprietary digital technology. Its care model provides personalized treatment across a spectrum from meditation to therapy to medications for patients with mild depression to severe schizophrenia. The multidisciplinary care team includes licensed social workers, mental health counselors, nurse practitioners, and psychiatrists. The company is led by CEO and co-founder Thomas Tsang, MD. Valera plans to use new capital for strategic market expansion and to grow existing services. The articles report total funding to date of $9M following the latest raise.

Participated · Seed · Nov 2021

Marker Learning offers remote learning and attention-disability evaluations and ongoing support, leveraging proprietary technology and a network of psychologists and educators. The company delivers comprehensive diagnostic reports within one month that can be submitted to schools or employers and used to secure test accommodations. Marker partners with school districts to act as an extension of special education teams and already reaches 1 million students through those partnerships. It aims to provide services at a fraction of the cost of traditional private evaluations—which can cost up to $14,000 and have waitlists beyond 24 months—to improve equity for students of color and low-income households. With Series A funding, Marker plans to expand into new geographies and broaden its platform to include tutoring, coaching, and other learning support services for individuals and schools. Co-founders Stefan Bauer and Emily Yudofsky, both diagnosed with dyslexia, lead the company. The company announced a $15 million Series A led by Andreessen Horowitz. Marker Learning operates a telepsychology platform that enables psychologists to virtually administer evidence-based learning disability assessments and deliver personalized action plans. The company partners with leading psychologists and learning-disability specialists and leverages proprietary technology to streamline the assessment process, reduce cost, and decrease turnaround time versus in-person services. Evaluations for dyslexia and other learning disabilities often cost over $10,000 and many cases go undiagnosed; Marker aims to make gold-standard assessments more accessible to schools and families. The platform was developed to address long waitlists and access issues that were exacerbated by the COVID-19 pandemic. Marker plans to use new funding to expand its team and accelerate geographic expansion across the United States. Co-founders Stefan Bauer and Emily Yudofsky started the company after their own diagnoses and bring experience from McKinsey, Google, and telemedicine entrepreneurship.

Participated · Series A · Aug 2021

Opya develops early intervention solutions for children with autism, combining clinical treatment with in-home and telehealth therapy. Its integrated, multidisciplinary model connects behavioral, speech, and occupational therapy with family training and in-home programs. The company is led by CEO Alden Romney and was founded by Jonathan Wright; it now has more than 100 employees. Opya intends to use the $15.4M Series A to scale its clinical care, add leadership talent, and accelerate product innovation. As part of the fundraise, Austin Poole of Panoramic Ventures will join Opya’s board alongside existing members including Romney, Wright, Jay Zeidman (Altitude Ventures), and Amol Deshpande (Divergent Investments).